WuXi Biologics Technology Co., Ltd. announced that it will hold a mid-term performance briefing conference call on August 22, 2024, to provide in-depth introduction of the company's financial indicators and business operation. The meeting will be conducted in both Chinese and English, and an online registration link will be provided. The company emphasizes the risk and uncertainty of forward-looking statements in the presentation, and reminds shareholders and potential investors not to overly rely on these data. In addition, the adjusted financial indicators mentioned in the company's announcement help to understand and evaluate business performance, but should not be viewed as a substitute for performance under international financial reporting standards. In the mid-term performance of WuXi Biologics...Show More

WuXi Biologics Technology Co., Ltd. announced that it will hold a mid-term performance briefing conference call on August 22, 2024, to provide in-depth introduction of the company's financial indicators and business operation. The meeting will be conducted in both Chinese and English, and an online registration link will be provided. The company emphasizes the risk and uncertainty of forward-looking statements in the presentation, and reminds shareholders and potential investors not to overly rely on these data. In addition, the adjusted financial indicators mentioned in the company's announcement help to understand and evaluate business performance, but should not be viewed as a substitute for performance under international financial reporting standards. In the mid-term performance of WuXi Biologics in 2024, the non-COVID-19-related income increased by 7.7% year-on-year, but the adjusted net profit decreased by 13% year-on-year, mainly due to the decrease in revenue from drug discovery services and increased investment for future development. The company expresses a positive attitude towards dealing with the potential impact of the proposed "Biosecurity Act," and reiterates the uniqueness of its CRDMO business model.